Epirus Biopharmaceuticals Stock Shares Outstanding
EPIRUS Biopharmaceuticals fundamentals help investors to digest information that contributes to EPIRUS Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of EPIRUS Pink Sheet. The fundamental analysis module provides a way to measure EPIRUS Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EPIRUS Biopharmaceutica pink sheet.
EPIRUS |
EPIRUS Biopharmaceuticals Company Shares Outstanding Analysis
EPIRUS Biopharmaceutica's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current EPIRUS Biopharmaceutica Shares Outstanding | 26.18 M |
Most of EPIRUS Biopharmaceutica's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EPIRUS Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, EPIRUS Biopharmaceuticals has 26.18 M of shares currently outstending. This is 85.5% lower than that of the Biotechnology sector and 75.5% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 95.42% higher than that of the company.
EPIRUS Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EPIRUS Biopharmaceutica's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of EPIRUS Biopharmaceutica could also be used in its relative valuation, which is a method of valuing EPIRUS Biopharmaceutica by comparing valuation metrics of similar companies.EPIRUS Biopharmaceutica is currently under evaluation in shares outstanding category among its peers.
EPIRUS Fundamentals
| Return On Equity | -1.22 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (37.45) % | |||
| Current Valuation | (6 M) | |||
| Shares Outstanding | 26.18 M | |||
| Number Of Shares Shorted | 252.54 K | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 701 K | |||
| Gross Profit | 576 K | |||
| EBITDA | (54.6 M) | |||
| Net Income | (52.19 M) | |||
| Cash And Equivalents | 20.86 M | |||
| Cash Per Share | 0.80 X | |||
| Total Debt | 14.85 M | |||
| Debt To Equity | 0.57 % | |||
| Current Ratio | 0.79 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (46.58 M) | |||
| Short Ratio | 0.07 X | |||
| Earnings Per Share | (2.52) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 73 | |||
| Beta | 4.28 | |||
| Market Capitalization | 157 | |||
| Total Asset | 72.26 M | |||
| Retained Earnings | (155.03 M) | |||
| Working Capital | (6.93 M) | |||
| Current Asset | 25.69 M | |||
| Current Liabilities | 32.63 M | |||
| Z Score | -2.8 | |||
| Net Asset | 72.26 M |
Pair Trading with EPIRUS Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EPIRUS Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPIRUS Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |